Phibro Animal Health Corporation (PAHC) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PAHC Revenue Growth
Revenue Breakdown (FY 2025)
PAHC's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
PAHC Revenue Analysis (2014–2025)
As of May 8, 2026, Phibro Animal Health Corporation (PAHC) generated trailing twelve-month (TTM) revenue of $1.46 billion, reflecting exceptional growth of +20.9% year-over-year. The most recent quarter (Q2 2026) recorded $373.9 million in revenue, up 2.8% sequentially.
Looking at the longer-term picture, PAHC's 5-year compound annual growth rate (CAGR) stands at +10.1%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $1.30 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows PAHC's business is primarily driven by Vaccines (100%). With over half of revenue concentrated in Vaccines, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ELAN (+10.5% YoY), ZTS (+2.4% YoY), and NEOG (-3.7% YoY), PAHC has outperformed the peer group in terms of revenue growth. Compare PAHC vs ELAN →
PAHC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PAHCCurrent | $1.5B | +20.9% | +10.1% | 8.5% | |
 ELAN | $4.7B | +10.5% | +7.6% | 5.3% | |
 ZTS | $9.5B | +2.4% | +7.2% | 38.0% | |
 NEOG | $895M | -3.7% | +16.4% | 1.1% | |
 IDXX | $4.3B | +13.1% | +9.7% | 31.6% | |
 TSN | $54.4B | +3.9% | +4.7% | 2.6% |
PAHC Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.30B | +27.4% | $399.9M | 30.9% | $110.5M | 8.5% |
| 2024 | $1.02B | +4.1% | $313.1M | 30.8% | $53.3M | 5.2% |
| 2023 | $977.9M | +3.8% | $298.2M | 30.5% | $71.8M | 7.3% |
| 2022 | $942.3M | +13.1% | $285.4M | 30.3% | $79.0M | 8.4% |
| 2021 | $833.4M | +4.1% | $271.4M | 32.6% | $74.9M | 9.0% |
| 2020 | $800.4M | -3.3% | $256.9M | 32.1% | $69.2M | 8.6% |
| 2019 | $828.0M | +1.0% | $264.6M | 32.0% | $73.3M | 8.9% |
| 2018 | $820.0M | +7.3% | $266.9M | 32.5% | $98.9M | 12.1% |
| 2017 | $764.3M | +1.7% | $248.3M | 32.5% | $97.9M | 12.8% |
| 2016 | $751.5M | +0.4% | $239.0M | 31.8% | $85.7M | 11.4% |
See PAHC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PAHC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PAHC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPAHC — Frequently Asked Questions
Quick answers to the most common questions about buying PAHC stock.
Is PAHC's revenue growth accelerating or slowing?
PAHC revenue is accelerating at +20.9% year-over-year, exceeding the 5-year CAGR of +10.1%. TTM revenue reached $1.5B. Growth momentum has increased versus prior periods.
What is PAHC's long-term revenue growth rate?
Phibro Animal Health Corporation's 5-year revenue CAGR of +10.1% reflects the sustained expansion pattern. Current YoY growth of +20.9% is above this long-term average.
How is PAHC's revenue distributed by segment?
PAHC reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.